<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745403</url>
  </required_header>
  <id_info>
    <org_study_id>LTCR-HCC-3-3</org_study_id>
    <nct_id>NCT04745403</nct_id>
  </id_info>
  <brief_title>Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)</brief_title>
  <acronym>SAFE-T-HBV</acronym>
  <official_title>Phase 1 Safety and Tolerability Study of Redirected HBV-Specific T Cells in Patients With Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (SAFE-T-HBV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lion TCR Pte. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lion TCR Pte. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center. single arm, open-label study to determine the safety of mRNA&#xD;
      modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment&#xD;
      caused by these HBV-TCR redirected T-cells in subjects with HBV-related HCC who are not&#xD;
      amenable to/failed conventional treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation of TCR-T treatment</measure>
    <time_frame>Start of treatment until 28 days post last dose</time_frame>
    <description>Based on assessments of adverse events (AEs) and serious AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of modifications of tumour microenvironment caused by TCR-T treatment using biopsy samples</measure>
    <time_frame>Start of treatment until 14 days post last dose</time_frame>
    <description>Based on immune gene expression changes determined by RNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of modifications of tumour microenvironment caused by TCR-T treatment using blood samples</measure>
    <time_frame>Start of treatment until 14 days post last dose</time_frame>
    <description>Based on changes in level of serum cytokines</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>mRNA HBV/TCR T-cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating regime from 1x10e5 to 5-10x10e6 cells/kg bodyweight (BW) every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mRNA HBV/TCR T-cells</intervention_name>
    <description>Study Infusion&#xD;
The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW.</description>
    <arm_group_label>mRNA HBV/TCR T-cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1&#xD;
&#xD;
          2. Presence of primary hepatocellular carcinoma in the liver with presence of measurable&#xD;
             tumour by RECIST 1.1 criteria, that is not amenable to, or failed, conventional&#xD;
             treatment options&#xD;
&#xD;
          3. Detectable HBV DNA integrations in the HCC tumour biopsy&#xD;
&#xD;
          4. Non-cirrhotic or compensated cirrhosis Child-Pugh A (5 - 6 points)&#xD;
&#xD;
          5. HLA class 1 profile matching HLA-class I restriction element of the available T cell&#xD;
             receptors (restricted by HLA-A0201, HLA-B5801, HLA-Cw0801)&#xD;
&#xD;
          6. Life expectancy of at least 3 months&#xD;
&#xD;
          7. Serum anti HBV core antibody positive (at any historical time)&#xD;
&#xD;
          8. Adequate organ function as defined below: a. Differential white blood counts within&#xD;
             normal reference ranges b. Serum aspartate aminotransferase (AST) and alanine&#xD;
             aminotransferase (ALT) ≤ 150 IU/ml c. Total conjugated serum bilirubin ≤ upper limit&#xD;
             normal (ULN) d. eGFR ≥ 60ml/minute e. Hemoglobin &gt; 10.0 mg/ dl f. Platelet count ≥&#xD;
             100,000/ μl&#xD;
&#xD;
          9. Willing and able to provide written, signed informed consent after the nature of the&#xD;
             study has been explained, and prior to any research-related procedures&#xD;
&#xD;
         10. Willing to undergo biopsy of non-tumour and tumour liver tissue before and after&#xD;
             treatment&#xD;
&#xD;
         11. Sexually active subjects must be willing to use an acceptable method of contraception&#xD;
             such as double barrier contraception during treatment and for 28 days after the last&#xD;
             dose of study drug&#xD;
&#xD;
         12. Females of childbearing potential must have a negative pregnancy test at Screening and&#xD;
             be willing to have additional pregnancy tests during the study. Females considered not&#xD;
             of childbearing potential include those who have been in menopause at least 2 years,&#xD;
             or had tubal ligation at least 1 year prior to Screening, or who have had total&#xD;
             hysterectomy&#xD;
&#xD;
         13. Willing and able to comply with all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Brain metastasis&#xD;
&#xD;
          2. Second primary malignancy that is clinically detectable at the time of consideration&#xD;
             for study enrolment&#xD;
&#xD;
          3. Use of checkpoint inhibitors within 6 months of baseline liver biopsy procedure&#xD;
&#xD;
          4. Alterations of concomitant medications within 3 months of baseline liver biopsy&#xD;
             procedure.&#xD;
&#xD;
          5. Likelihood to require any immunosuppressive treatments during the period of the&#xD;
             clinical trial.&#xD;
&#xD;
          6. Patient's last RFA/TACE, or Y90 therapy is less than 3 and 6 months ago, respectively.&#xD;
&#xD;
          7. Decompensated cirrhosis Child-Pugh B or C (7 - 15 points)&#xD;
&#xD;
          8. Concurrent administration of any other anti-tumour therapy, including cytotoxic&#xD;
             chemotherapy, hormonal therapy, and immunotherapy.&#xD;
&#xD;
          9. Use of any investigational product (IP) or investigational medical device within 30&#xD;
             days of study drug administration&#xD;
&#xD;
         10. Poorly controlled medical illness that in the opinion of the investigator would&#xD;
             compromise the patient's ability to tolerate therapy&#xD;
&#xD;
         11. Uncontrolled hypertension, defined as systolic blood pressure &gt;160 mmHg or diastolic&#xD;
             pressure &gt;110 mmHg, despite optimal medical management&#xD;
&#xD;
         12. Serum HBV DNA levels ≥ 200 IU/ml at screening&#xD;
&#xD;
         13. Serum HBsAg levels ≥ 10,000 IU/ml at screening&#xD;
&#xD;
         14. Lack of peripheral venous or central venous access or any condition that would&#xD;
             interfere with drug administration or collection of study samples&#xD;
&#xD;
         15. Substance abuse, medical, psychological, or social conditions that may interfere with&#xD;
             the subject's participation in the study or evaluation of study results.&#xD;
&#xD;
         16. Any condition or active infections which, in the investigator's opinion, makes the&#xD;
             subject unsuitable for trial participation&#xD;
&#xD;
         17. Women who are pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Royce Fam</last_name>
    <phone>69260818</phone>
    <email>royce.fam@liontcr.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <contact>
      <last_name>Thinesh L Krishnamoorthy</last_name>
      <phone>62223322</phone>
      <email>thinesh.l.krishnamoorthy@singhealth.com.sg</email>
    </contact>
    <contact_backup>
      <phone_ext>Krishnamoorthy</phone_ext>
      <email>thinesh.l.krishnamoorthy@singhealth.com.sg</email>
    </contact_backup>
    <investigator>
      <last_name>Thinesh L Krishnamoorthy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <results_reference>
    <citation>Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, Renia L, Sällberg M, Campana D, Bertoletti A. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids. 2013 Aug 13;2:e114. doi: 10.1038/mtna.2013.43.</citation>
    <PMID>23941866</PMID>
  </results_reference>
  <results_reference>
    <citation>Kah J, Koh S, Volz T, Ceccarello E, Allweiss L, Lütgehetmann M, Bertoletti A, Dandri M. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J Clin Invest. 2017 Aug 1;127(8):3177-3188. doi: 10.1172/JCI93024. Epub 2017 Jul 24.</citation>
    <PMID>28737510</PMID>
  </results_reference>
  <results_reference>
    <citation>Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, Tan HS, Chia A, Le Bert N, Low D, Tan HK, Kumar R, Irani FG, Ho ZZ, Zhang Q, Guccione E, Wai LE, Koh S, Hwang W, Chow WC, Bertoletti A. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology. 2019 May;156(6):1862-1876.e9. doi: 10.1053/j.gastro.2019.01.251. Epub 2019 Jan 31.</citation>
    <PMID>30711630</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B virus</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

